Esperion
The Lipid Management Company

Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website
Sign-up for Email alerts

| NASDAQ: ESPR | |
|---|---|
| Last Trade: | 49.19 |
| Trade Time: | 4:00 PM ET Nov 17, 2017 |
| Change: | -0.30 (-0.606%) |
| Day Range | 48.50 - 49.54 |
| 52-Week Range | 10.30 - 57.40 |
| Volume | 275,099 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

## Stock Performance




## Press Releases [ View all ]

*Nov 13, 2017*
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference

*Nov 9, 2017*
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference

*Nov 7, 2017*
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results

*Nov 6, 2017*
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

*Oct 10, 2017*
Esperion to Host Analyst and Investor Day Event on October 17

## Financials [ View all ]

Third Quarter Financial Results

*Feb 22, 2017*
Annual Report (10-K)

*Mar 6, 2017*
Proxy Statement (DEF 14A)

*Nov 7, 2017*
Quarterly Report (10-Q)

*Aug 8, 2017*
Quarterly Report (10-Q)

*May 4, 2017*
Quarterly Report (10-Q)